WO2015067089A1 - 外源线粒体导入到哺乳动物细胞中的方法 - Google Patents
外源线粒体导入到哺乳动物细胞中的方法 Download PDFInfo
- Publication number
- WO2015067089A1 WO2015067089A1 PCT/CN2014/085117 CN2014085117W WO2015067089A1 WO 2015067089 A1 WO2015067089 A1 WO 2015067089A1 CN 2014085117 W CN2014085117 W CN 2014085117W WO 2015067089 A1 WO2015067089 A1 WO 2015067089A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mitochondria
- dna
- mitochondrial
- exogenous
- mammalian
- Prior art date
Links
- 210000003470 mitochondria Anatomy 0.000 title claims abstract description 107
- 238000000034 method Methods 0.000 title claims abstract description 42
- 210000004962 mammalian cell Anatomy 0.000 title claims abstract description 33
- 108020005196 Mitochondrial DNA Proteins 0.000 claims abstract description 56
- 210000004027 cell Anatomy 0.000 claims abstract description 49
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 108091029865 Exogenous DNA Proteins 0.000 claims abstract description 19
- 230000012202 endocytosis Effects 0.000 claims abstract description 12
- 238000003209 gene knockout Methods 0.000 claims abstract description 8
- 230000008707 rearrangement Effects 0.000 claims abstract description 8
- 108020004414 DNA Proteins 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 23
- 210000002540 macrophage Anatomy 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 230000002121 endocytic effect Effects 0.000 claims description 4
- 238000003144 genetic modification method Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000010369 molecular cloning Methods 0.000 abstract description 6
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000003198 gene knock in Methods 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 description 20
- 239000000872 buffer Substances 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000012546 transfer Methods 0.000 description 11
- 238000012239 gene modification Methods 0.000 description 10
- 230000005017 genetic modification Effects 0.000 description 10
- 235000013617 genetically modified food Nutrition 0.000 description 10
- 239000008188 pellet Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- 108091064355 mitochondrial RNA Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 230000004103 aerobic respiration Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- NHUWXMNVGMRODJ-UHFFFAOYSA-P 10-methoxy-2-[2-[4-[1-[2-(10-methoxy-7h-pyrido[4,3-c]carbazol-2-ium-2-yl)ethyl]piperidin-4-yl]piperidin-1-yl]ethyl]-7h-pyrido[4,3-c]carbazol-2-ium Chemical compound N1C2=CC=C(OC)C=C2C(C2=C3)=C1C=CC2=CC=[N+]3CCN(CC1)CCC1C(CC1)CCN1CC[N+]1=CC2=C(C=3C(=CC=C(C=3)OC)N3)C3=CC=C2C=C1 NHUWXMNVGMRODJ-UHFFFAOYSA-P 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 1
- 230000025608 mitochondrion localization Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to the field of biological genetic engineering, and in particular to a method for introducing foreign mitochondria into mammalian cells. Background technique
- Mitochondria are the most important organelles of eukaryotes, responsible for more than 90% of the energy supply of cells. Mitochondria carry independent genomes, mitochondrial DNA, independent genetic transcription and protein translation structures different from the nuclear genome, mammalian cell mitochondrial DNA coding. There are 22 tRNAs, 2 rRNAs, and 13 peptides. These encoded polypeptides are very critical subunits in various protein complexes of mitochondria for aerobic respiration. Numerous studies have shown that mutations or decreased expression of these polypeptides can significantly inhibit cellular aerobic respiration.
- the third option is to use the techniques of nuclear transfer or cell cytoplasmic hybridization to increase the proportion of exogenous wild-type mitochondria to achieve the transformation of mitochondrial genetic behavior. This type of method does not eradicate endogenous mitochondria and DNA, and this method adds an extra amount of exogenous cytoplasmic components, which introduces some uncertainties.
- the fourth option is to express TALEN molecules that target mitochondria to achieve destruction of the target sequence.
- This method has been reported to successfully disrupt mitochondrial DNA with large fragment deletions and specific point mutations, and is the most effective technique for engineering mitochondrial DNA that has been reported so far.
- this method can only specifically destroy specific sequences, yet The method is to achieve fixed point genetic modification and gene introduction.
- Humans have discovered mitochondria for more than a hundred years, and have discovered mitochondrial DNA and committed to mitochondrial DNA transformation for decades.
- effective genetic modification of mitochondrial DNA in mammals has not been achieved, effective mammalian line cells.
- the mitochondrial genetic modification technology is a world-class technical problem. The entire sequence of mouse mitochondrial DNA, but without any modification, did not achieve artificial synthesis of mitochondria
- one of the objects of the present invention is to provide a mammalian cell containing exogenous mitochondria.
- the technical solution to achieve this is as follows:
- Mammalian cells containing exogenous mitochondria having endocytic function endocytosis.
- the mitochondria are artificially synthesized mitochondria obtained by introducing exogenous DNA into mitochondria or mitochondrial vesicles, and may also be isolated mammalian cell mitochondria.
- the exogenous DNA may be artificially synthesized mitochondrial DNA or may be isolated DNA.
- the exogenous DNA is artificially synthesized mitochondrial DNA, and the source thereof is not limited.
- the synthetic mitochondrial DNA is an artificially genetically engineered mammalian cell mitochondrial DNA.
- the synthetic mitochondrial DNA may also be wild-type mammalian cell mitochondrial DNA.
- the mammalian cell of the present invention refers to a cell having endocytic function, and most preferably a macrophage.
- Another object of the present invention is to provide a method for producing the above-described cells containing exogenous mitochondria.
- Exogenous mitochondria are added to a cell culture system in which mammalian cells having endocytosis are cultured, and the cells are cultured to obtain cells containing exogenous mitochondria.
- the mammalian cell is a macrophage; the culture condition is: 36-38 ° C, a water-saturated closed incubator, 4.5-5.5% C0 2 .
- Another object of the invention is to provide a synthetic mitochondria.
- a method for preparing a synthetic mitochondria includes the following steps:
- the exogenous DNA is isolated wild type DNA; or the exogenous DNA is synthetic mitochondrial DNA, and the synthetic mitochondrial DNA preparation comprises the following steps:
- Another object of the present invention is to provide a method of introducing foreign mitochondria into a cell.
- a method of introducing a foreign mitochondria into a mammalian cell comprising the steps of:
- the exogenous mitochondria obtained in the step (1) are added to a cell culture system in which mammalian cells having endocytosis are cultured, and culture is continued to obtain cells containing exogenous mitochondria.
- the exogenous mitochondria are mitochondria of isolated mammalian cells Body.
- the exogenous mitochondria are synthetic mitochondria obtained by introducing exogenous DNA into mitochondria or mitochondrial vesicles.
- the exogenous DNA is isolated wild type DNA.
- the exogenous DNA is synthetic mitochondrial DNA
- the synthetic mitochondrial DNA preparation comprises the steps of:
- the mammalian cell is a macrophage.
- the culture condition is: 36-38 ° C, water-saturated closed incubator, 4.5-5.5%
- the invention utilizes synthetic biological technology to artificially synthesize the complete sequence of mitochondrial DNA, and realizes the fusion expression of GFP and COX-I on the basis of the wild type sequence, which provides a simple and effective technical method for cloning the mitochondrial genome.
- the invention introduces exogenous mitochondrial DNA into cells based on macrophage endocytosis, enables the gene in the exogenous mitochondria to be stably expressed in mammalian cells, and can be effectively passaged, thereby realizing the utilization of exogenous mitochondria in the cell. Effective function.
- the method can be used as a novel mitochondrial molecular cloning method to achieve site-directed mutagenesis, gene insertion, gene knockout, gene rearrangement, etc. in mitochondria, thereby realizing any molecular cloning transformation of mammalian mitochondrial DNA without source limitation. High purity is of great significance for the treatment of diseases with mitochondrial DNA mutations.
- Figure 1 shows the results of exogenous mitochondria entering macrophages as described in Example 1.
- Figure 1A shows the results of DsRed2 detection, indicating exogenous mitochondria derived from NIH3T3.
- Figure 1B shows the results of the EYFP assay, which represents the endogenous mitochondria of macrophages.
- Figure 1C shows the two-color overlay effect.
- Figure 2 is an in vitro assembled synthetic mitochondria as described in Example 3; Figure 2A is the detection of the correct transcript in the assembled synthetic mitochondria, and Figure 2B is the detection of DNA replication in the assembled synthetic mitochondria.
- Figure 3 is a fusion expression of GFP-COX I described in Example 4 in mouse macrophage RAW264.7, and Figure 3A shows the location of all mitochondria in the cell indicated by Mito-Tracker Red dye staining.
- the mitochondria-specific dye Figure 3B shows the GFP signal of the green GFP-COX I fusion gene
- Figure 3C shows the DAPI staining result, indicating the position of the nucleus
- Figure 3D shows the result of the three-color overlay.
- the genetic modification in the present invention refers to the construction of a target sequence of deoxyribonucleic acid (DNA) molecules by in vitro design and total synthesis, and these molecules can be any artificially designed sequences.
- the genetic modification of the present invention can be designed according to the requirements of the mammalian mitochondrial DNA sequence. Sequences that are identical to wild-type or undergo any sequence modification, including site-directed mutagenesis, gene insertion, gene knockout, and gene rearrangement.
- Endocytosis also known as inoculation, is the process of transporting extracellular substances into cells through the deformation movement of the plasma membrane. Endocytosis can be divided into three types depending on the size of the influent material and the mechanism of cell entry: phagocytosis, swallowing, receptor-mediated endocytosis.
- Example 1 The experimental methods in the following examples which do not specify the specific conditions are usually prepared according to the conditions described in the conventional conditions, for example, Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturing conditions. The conditions recommended by the manufacturer. The various common chemical reagents used in the examples are commercially available products.
- Example 1 The various common chemical reagents used in the examples are commercially available products.
- the mitochondrial endogenous mitochondria were labeled with EYFP by stably expressing the mitochondrial-targeted fluorescent protein EYFP in macrophages, and the mitochondrial fluorescent protein DsRed2 was stably expressed in NIH3T3 cells, and the mitochondria of NIH3T3 cells were labeled with DsRed2. Isolation of NIH3T3 mitochondria with DsRed2 labeling, and addition to macrophage culture system, 12 hours later, in the confocal microscope, DsRed2-labeled mitochondria enter macrophages, which can be expressed with macrophages.
- the mitochondria consistent morphology of the EYFP marker. Specifically:
- Mouse macrophage cell line RAW264.7 cells and NIH3T3 cell culture medium (high glucose DMEM (purchased from Hyclone, article number: SH30022.01B); 10% fetal bovine serum (purchased from GIBCO, article number: 16000-044); Double antibody (containing 10000 U/ml penicillin and 1000 g/ml streptomycin, diluted 1:100, purchased from GIBCO, Cat. No.: 15140-122)), cultured according to the conventional method.
- high glucose DMEM purchased from Hyclone, article number: SH30022.01B
- 10% fetal bovine serum purchased from GIBCO, article number: 16000-044
- Double antibody containing 10000 U/ml penicillin and 1000 g/ml streptomycin, diluted 1:100, purchased from GIBCO, Cat. No.: 15140-122)
- the mitoDsRed2 and mitoEYFP plasmids were constructed by molecular cloning, using standard Ds ed2 ( GenBank: AFS63392.1 ) and EYFP ( GenBank: AC048266.1 ) fluorescent protein sequences at the N-terminus plus mitochondrial localization sequence signals.
- MSVLTPLLLRGLTGSARRLPVPRAKIHSL was constructed in pMXs vector, transfected into corresponding cells by electroporation, and serially cultured in a single cell to obtain a cell line stably expressing fluorescent protein.
- a circular mitochondrial DNA ie, a circular mitochondrial DNA containing a GFP-COX-I fusion gene, is obtained by introducing a GFP and a Linker sequence into a mouse mitochondrial DNA by inserting a GFP and a Linker sequence, primer synthesis, and DNA splicing. .
- This example is to obtain circular mitochondrial DNA by gene introduction into mouse mitochondrial DNA, ie, inserting GFP and Linker sequences, specifically, based on the known mitochondrial DNA sequence of wild-type C57 BL/6J mice (sequence source) : NCBI GenBank: EF108336 ) and inserted the GFP gene and Linker sequence at 5328 (specifically as shown in Seq. ID No.1), designed to obtain a circular mitochondria containing GFP-COX-I fusion gene of about 5Kb. DNA.
- a plurality of DNA fragments of 50 bp to 60 bp to be spliced are obtained by a common primer synthesis method.
- the Gibson isothermal one-step method is used for DNA splicing
- the Gibson isothermal one-step enzyme system is: 320 ⁇ l 5 ⁇ ISO buffer (25% PEG-8000, 500 mM Tris-HCl pH 7.5, 50 mM MgCl). 2 , 50 mM DTT, 4 dNTPs each 1 mM, 5 mM NAD), 0.64 ⁇ 10 U/ ⁇ T5 exonuclease Epicentre, 20 ⁇ 2 U/ ⁇ Phusion polymerase, 160 ⁇ 40 U/ ⁇ Taq ligase Mix, add sterile water to 1.2 ml, and store at -20 °C after stocking;
- the fragments to be spliced are mixed in equal proportions to a final concentration of 2 ng/ ⁇ ; 5 ⁇ 1 mixture, 15 ⁇ 1 of the above enzyme system, mixed, and incubated at 50 ° C for 1 hour, Get the correct stitched piece.
- This example describes the in vitro assembly of the mitochondrial DNA obtained in Example 2 with the mitochondrial vesicle of NIH3T3 RhoO cells to prepare a synthetic mitochondria, and the process of extracting and identifying RNA and DNA from artificially synthesized mitochondria.
- Figure 2 shows the correct transcript (Figure 2A) and DNA replication ( Figure 2B) detected in synthetic mitochondria.
- NIH3T3 RhoO medium high glucose DMEM, 10% fetal bovine serum, 5 ( ⁇ g/mL uridine, llO g/mL sodium pyruvate, penicillin and streptomycin)
- Incubation buffer 1 40mM Tri-HCl 7.4; 25mM NaCl; 5mM MgC12; 10% glycerol
- lml washing buffer (10% glycerol; 1 OmM Tri-HCl 7.4; 150 mM NaCl; ImM EDTA) was washed three times and centrifuged at 1000 g/min at 4 ° C for 10 min.
- RNA eluted in the EP tube is re-column, centrifuged at room temperature for more than 8000 g for 1 min;
- RNA 8 ⁇ 1 (2) After digestion, add ⁇ stop buffer and treat lOmin at 65 °C;
- the PCR reaction system is as follows:
- PrimeSTAR enzyme (2.5 U/ ⁇ ) 0.5 ⁇
- the PCR product was electrophoresed on a 1.5% agarose gel and photographed. The results are shown in Figure 1A.
- the "positive” lane is the PCR product of the cDNA isolated from the mitochondrial RNA in NIH3T3 cells.
- the "pathway” is the PCR product of the cDNA isolated after electroporation, and the "negative” lane is the PCR product using only water as a template.
- This example is a process in which a synthetic mitochondria containing a GFP-COX-I fusion gene is endocytosed into a mouse macrophage cell line, and the results are shown in Fig. 3.
- Mouse macrophage cell line RAW264.7 cell culture medium high glucose DMEM (purchased from Hyclone, article number: SH30022.01B), 10% fetal bovine serum (purchased from GIBCO, article number: 16000-044), double antibody (containing 10000 U/ml penicillin and lOOOO g/ml streptomycin, 1:100 diluted use, purchased from GIBCO, item number: 15140-122)), according to the conventional method, plate culture;
- Example 3 The artificially synthesized mitochondria obtained by electroporation in Example 3 were precipitated, resuspended in 20 ( ⁇ LRAW264.7 cell culture medium, uniformly added to the divided culture medium, and the water-saturated closed incubator was stirred at 37 °C. After cultured at 5% C0 2 , mouse macrophages containing exogenous mitochondria expressing green fluorescent protein were observed after 12 hours of endocytosis. After 12 hours of culture, the cells were changed and cultured for 12 hours. Identification, the results obtained are shown in Figure 3.
- Fig. 3A shows the results of Mittotracker Red staining of the mitochondria-specific dye.
- Figure 3B shows the results of GFP detection.
- Figure 3C is DAPI staining indicating the nuclear position.
- Figure 3D shows the three-color overlay effect.
- This example demonstrates stable expression in macrophages by the designed GFP-COX I fusion gene.
- the isolated untransformed mitochondria for example, isolated mitochondria, or synthetic mitochondria whose DNA sequence is wild-type mammalian mitochondrial DNA
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016528071A JP6741579B2 (ja) | 2013-11-08 | 2014-08-25 | 哺乳類細胞内に外来性ミトコンドリアを導入するための方法 |
EP14860811.0A EP3067416B1 (en) | 2013-11-08 | 2014-08-25 | Method for introducing exogenous mitochondria into mammalian cells |
US15/034,687 US20170159017A1 (en) | 2013-11-08 | 2014-08-25 | Method For Introducing Exogenous Mitochondria Into A Mammalian Cell |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310554218.7 | 2013-11-08 | ||
CN201310554218.7A CN104630149B (zh) | 2013-11-08 | 2013-11-08 | 外源线粒体导入到哺乳动物细胞中的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015067089A1 true WO2015067089A1 (zh) | 2015-05-14 |
Family
ID=53040869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/085117 WO2015067089A1 (zh) | 2013-11-08 | 2014-08-25 | 外源线粒体导入到哺乳动物细胞中的方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170159017A1 (zh) |
EP (1) | EP3067416B1 (zh) |
JP (1) | JP6741579B2 (zh) |
CN (1) | CN104630149B (zh) |
WO (1) | WO2015067089A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018088875A3 (ko) * | 2016-11-14 | 2018-08-09 | 주식회사 파이안에스테틱스 | 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 |
RU2777371C2 (ru) * | 2016-11-14 | 2022-08-02 | Пэан Байотекнолоджи Инк. | Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019018497A1 (en) * | 2017-07-18 | 2019-01-24 | President And Fellows Of Harvard College | INTRACELLULAR DELIVERY USING MICROFLUIDIC ASSISTED CELLULAR SCREENING (MACS) |
US20210238249A1 (en) * | 2018-04-26 | 2021-08-05 | Paean Biotechnology Inc. | Modified mitochondria and use thereof |
US20220162651A1 (en) * | 2019-03-08 | 2022-05-26 | Synvitrobio, Inc. | Methods and Compositions for Cell-Free Biological Reactions |
CN113930397B (zh) * | 2021-11-05 | 2024-02-20 | 曲阜师范大学 | 酵母细胞线粒体移植乳腺肿瘤细胞的构建培养方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038564A2 (en) * | 2005-09-28 | 2007-04-05 | Massachusetts Institute Of Technology | Global transcription machinery engineering |
CN103173441A (zh) * | 2013-02-05 | 2013-06-26 | 深圳华大基因研究院 | 线粒体全基因组dna扩增、引物、测序及突变检测 |
CN103205463A (zh) * | 2005-09-08 | 2013-07-17 | 奥尔胡斯大学 | 细胞核移植 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9319772D0 (en) * | 1993-09-24 | 1993-11-10 | Therexsys Ltd | Therapeutic agent |
US5698421A (en) * | 1995-09-12 | 1997-12-16 | The Ohio State Research Foundation | Ribonucleoprotein particles for cleaving double-stranded DNA and inserting an RNA/DNA molecule into the cleavage site |
FR2795415B1 (fr) * | 1999-06-28 | 2003-09-05 | Roussy Inst Gustave | Compose peptidique derive d'une orf decalee du gene ice |
JP3780333B2 (ja) * | 2000-09-22 | 2006-05-31 | 国立大学法人大阪大学 | 外来性遺伝物質又は生理活性物質を細胞内へ導入する新規な方法 |
AU2002330938A1 (en) * | 2001-07-31 | 2003-02-17 | Northeastern University | Mitochondrial genome replenishment |
EP1681346A4 (en) * | 2003-08-29 | 2006-11-02 | Soiken Inc | HHV-6 OR HHV-7 DERIVED RECOMBINANT VIRUS VECTOR, METHOD FOR THE PRODUCTION THEREOF, METHOD FOR TRANSFORMING A HOST CELL USING THEREOF, TRANSFORMED HOST CELL AND GENE THERAPY METHOD USING THEREOF |
EP2418281B1 (en) * | 2003-10-24 | 2016-06-01 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
US8420377B2 (en) * | 2004-04-15 | 2013-04-16 | Michael D. Koob | Transgenomic mitochondria, transmitochondrial cells and organisms, and methods of making and using |
AU2008216018B2 (en) * | 2007-02-16 | 2012-10-25 | John Guy | Mitochondrial nucleic acid delivery systems |
US20130022666A1 (en) * | 2011-07-20 | 2013-01-24 | Anna Brzezinska | Methods and compositions for transfer of mitochondria into mammalian cells |
US8648034B2 (en) * | 2011-12-09 | 2014-02-11 | Changhua Christian Hospital | Method and applications of peptide-mediated mitochondrial delivery system |
-
2013
- 2013-11-08 CN CN201310554218.7A patent/CN104630149B/zh active Active
-
2014
- 2014-08-25 EP EP14860811.0A patent/EP3067416B1/en active Active
- 2014-08-25 JP JP2016528071A patent/JP6741579B2/ja active Active
- 2014-08-25 US US15/034,687 patent/US20170159017A1/en not_active Abandoned
- 2014-08-25 WO PCT/CN2014/085117 patent/WO2015067089A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103205463A (zh) * | 2005-09-08 | 2013-07-17 | 奥尔胡斯大学 | 细胞核移植 |
WO2007038564A2 (en) * | 2005-09-28 | 2007-04-05 | Massachusetts Institute Of Technology | Global transcription machinery engineering |
CN103173441A (zh) * | 2013-02-05 | 2013-06-26 | 深圳华大基因研究院 | 线粒体全基因组dna扩增、引物、测序及突变检测 |
Non-Patent Citations (3)
Title |
---|
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP3067416A4 |
WEI, YUE ET AL.: "Inheritance Analysis of Mitochondrial (mt)DNA in the Interspecific Crossing of Genus Cucumis", JOURNAL OF PLANT GENETIC RESOURCES, vol. 12, no. 4, 31 August 2011 (2011-08-31), pages 612 - 618, XP055342812 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018088875A3 (ko) * | 2016-11-14 | 2018-08-09 | 주식회사 파이안에스테틱스 | 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 |
US11278569B2 (en) | 2016-11-14 | 2022-03-22 | Paean Biotechnology Inc. | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same |
RU2777371C2 (ru) * | 2016-11-14 | 2022-08-02 | Пэан Байотекнолоджи Инк. | Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку |
Also Published As
Publication number | Publication date |
---|---|
EP3067416B1 (en) | 2020-04-01 |
US20170159017A1 (en) | 2017-06-08 |
JP6741579B2 (ja) | 2020-08-19 |
EP3067416A4 (en) | 2017-10-04 |
EP3067416A1 (en) | 2016-09-14 |
CN104630149B (zh) | 2018-08-21 |
JP2016535598A (ja) | 2016-11-17 |
CN104630149A (zh) | 2015-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111770992B (zh) | CRISPR-Cas12j酶和系统 | |
CN107502608B (zh) | 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用 | |
Pardi et al. | In vitro transcription of long RNA containing modified nucleosides | |
WO2015067089A1 (zh) | 外源线粒体导入到哺乳动物细胞中的方法 | |
CN106755091A (zh) | 基因敲除载体,mh7a细胞nlrp1基因敲除方法 | |
CN107880132A (zh) | 一种融合蛋白及使用其进行同源重组的方法 | |
WO2019086007A1 (zh) | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA | |
CN113015798B (zh) | CRISPR-Cas12a酶和系统 | |
EP4159853A1 (en) | Genome editing system and method | |
CN106967716A (zh) | 双gRNA、双gRNA文库、双gRNA载体文库及其制备方法和应用 | |
CN108148866B (zh) | 一种hcbp6基因敲除细胞系及其构建方法 | |
CN114438110A (zh) | 一种精确无pam限制的腺嘌呤碱基编辑器及其构建方法 | |
Shi et al. | DNA topology regulates PAM-Cas9 interaction and DNA unwinding to enable near-PAMless cleavage by thermophilic Cas9 | |
CN109456995A (zh) | 基因敲除质粒、细胞系及制备方法和应用 | |
KR20240049306A (ko) | Ruvc 도메인을 갖는 효소 | |
WO2020098806A1 (zh) | 鉴定rna分子中2'-o-甲基化修饰的方法及其应用 | |
CN109504711A (zh) | 基于CRISPR/cas9和过氧化物酶APEX2系统识别分析特异性基因组位点相互作用DNA的方法 | |
CN114891786B (zh) | 犬Rosa26基因及其应用 | |
CN114703162B (zh) | 一种具有高转录活性的t7 rna聚合酶突变体及其应用 | |
CN113025637A (zh) | 一种细菌源性的抗肿瘤PNPase基因及其制备方法与应用 | |
Barakat | Structure-Guided Engineering of AceCas9 to Relax the PAM Requirement | |
Han et al. | Efficient Large DNA Fragment Knock-in by Long dsDNA with 3′-Overhangs Mediated CRISPR Knock-in (LOCK) in Mammalian Cells | |
Yang et al. | THUMPD2 catalyzes N2-methylation on the spliceosome catalytic center of U6 snRNA and regulates pre-mRNA splicing | |
CN104560996B (zh) | 一种抑制小鼠GH基因表达的shRNA的载体及其应用 | |
CN114891791A (zh) | 特异性靶向犬Rosa26基因的sgRNA及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14860811 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15034687 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016528071 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014860811 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014860811 Country of ref document: EP |